PBM Integration: Economists Outline Benefits Of Mergers In Senate Hearing
Recent mergers between PBMs and insurers should address one long-term strategic objective of pharma – the recognition by payors of the value of biopharmaceutical products in relation to other medical costs.
You may also be interested in...
Divestiture prevents CVS from gaining even more dominance in the stand-alone Medicare Part D sector with its acquisition of Aetna, assuming the transaction is cleared by the government.
The political dynamics of the health care debate are changing again, and now Democrats are likely to return to universal coverage as a high-profile campaign theme. Is there a US “single-payer” model that might actually work out for biopharma innovators?
National Academies report argues that technologies cannot only be evaluated in the context of specific products, and FDA guidance should become both ‘more fluid and targeted.’